Full Breakdown
ASPS Position on Gender-Affirming Surgery for Minors Sparks Professional Controversy
6/29/2026, 10:41:08 PM
Core Event: ASPS Sets Age-19 Limit on Gender-Affirming Surgery
In February, the American Society of Plastic Surgeons (ASPS) issued a position statement recommending that gender-affirming surgery not be performed on individuals under 19 years. The statement has been cited by the Trump administration to support restrictions on gender-affirming care.
Background & Context: Plastic Surgery’s Evolving Role in Trans Care
Since Medicare and Medicaid began covering transition-related services in 2014, plastic surgeons have become a leading provider of gender-affirming operations. Earlier ASPS initiatives included symposia, grant funding, and endorsement. The specialty’s evidence base relies on observational studies, as randomized controlled trials comprise fewer than 3 % of plastic-surgery publications.
Data & Statistics: Outcomes and Procedure Frequency
Observational data report mental-health improvements and low complication rates, with a 1 %–4 % regret rate after gender-affirming surgery. In 2019, no procedures were performed on patients <= 12 years, and rates for ages 13-16 were 0.1-2.1 per 100,000 minors.
Official Statements & Responses
ASPS cites insufficient evidence for younger patients as the basis for its age-19 recommendation. American Academy of Pediatrics and American Medical Association affirm transgender patients’ right to medically indicated care. Trump administration has invoked the ASPS statement to bolster its agenda. WHO defines adolescence as ages 10-19 and does not set surgical thresholds. ASPS has not banned procedures such as the Brazilian butt lift.
Criticism & Opposition
The surgeon notes that ASPS permits breast implants for cisgender women at age 18, yet sets a 19-year minimum for trans women undergoing the identical procedure. No peer-reviewed study justifies the specific cutoff. Critics argue that the statement misuses “weak evidence” to limit care and relies on articles funded by the Society for Evidence-Based Gender Medicine and the Department of Health and Human Services under Robert F. Kennedy Jr., risking professional credibility and patient trust.
Conflicting Reports & Gaps
ASPS emphasizes limited evidence, yet observational data show mental-health benefits and low complication rates for youth. The statement omits the rarity of surgeries in early adolescence—zero procedures for ages <= 12 and 0.1-2.1 per 100,000 for ages 13-16 in 2019. Funding shortages impede higher-quality research, leaving a gap between policy rationale and empirical findings.
Verbatim Quotes
- “Low-quality evidence is different from saying that treatment is harmful.” — Kavitha Ranganathan, M.D., M.S.
- “The reality of my job today is that I can see a young girl in my clinic for breast augmentation in preparation for her sweet 16 and be prosecuted for doing the same operation on a 19-year-old with gender dysphoria.” — Kavitha Ranganathan, M.D., M.S.
- “The operation for both is exactly the same.” — Kavitha Ranganathan, M.D., M.S.
- “The government’s opinion shouldn’t infringe on autonomy.” — Kavitha Ranganathan, M.D., M.S.
What’s Next: Research-Driven Policy Recommendations
The surgeon calls on ASPS to create research protocols that standardize adolescent gender-affirming care at regional centers of excellence and to prioritize long-term outcome tracking. Ongoing legal challenges to subpoenas may influence future regulatory approaches.
